Please login to the form below

Not currently logged in
Email:
Password:

Almirall sees Q1 profit fall

Almirall says its first-quarter profit has been hit by generic competition

Spain-based Almirall has posted a 40 per cent fall in earnings before interest and tax to €37.9m for the first quarter of 2011, due to price erosion and generic competition.

The company's net sales fell by 12.3 per cent to €212.7m, with stable evolution of the international business in Europe, which grew by 0.1 per cent, while its domestic business fell by 14 per cent.

Eduardo Sanchiz, chief financial officer, said: "The year has started with very positive corporate development agreements like aclidinium bromide in Japan and roflumilast in Spain. Later this year we aim to partner aclidinium bromide in Europe as we continue in-licensing efforts around core therapies.

"We maintain our strategic priorities with continued focus on innovation and long-term sustainable growth."

Almirall reached a commercialisation agreement with Nycomed for roflumilast in Spain. The anti-inflammatory product for the treatment of COPD, an entirely new class of treatment, is due to be registered in mid-2011 in Europe and the US.

12th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics